US Bancorp’s Alto Neuroscience ANRO Stock Holding History

US Bancorp’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.47K	Sell	110 -3	-3%	-$56	﹤0.01%	3756
2025 Q4	$2.01K	Buy	+113	New	+$1.42K	﹤0.01%	3752
2024 Q4	–	Sell	-17	Closed	-$194	–	4279
2024 Q3	$194	Buy	+17	New	+$208	﹤0.01%	4015

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

US Bancorp's ANRO Position: Q1 2026 in Review

US Bancorp reduced its Alto Neuroscience (ANRO) stake by 2.7% in Q1 2026, selling an estimated $56 and leaving 110 shares worth $2.47K. The position accounts for ﹤0.01% of the portfolio, ranked #3756.

US Bancorp first reported a position in ANRO in Q3 2024 and has held it in 3 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

US Bancorp held 110 shares of Alto Neuroscience worth $2.47K as of Q1 2026.
US Bancorp sold 3 Alto Neuroscience shares in Q1 2026, an estimated $56.
Alto Neuroscience made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3756 holding.
US Bancorp first reported a position in Alto Neuroscience in Q3 2024 and has held it in 3 quarters since.
110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.